NEW YORK (AP) — Seattle Genetics Inc. said today its potential cancer drug
SGN-35 met key goals in a pivotal study.
The company is testing the drug candidate as a potential treatment for
Hodgkin’s lymphoma. The study involved 102 patients, with 75 percent of the
patients achieving an objective response to the drug candidate.
The company said a more complete data set will be presented at an upcoming
scientific meeting.
In premarket trading, shares rallied to $13.60, up 12 percent from Friday’s
close of $12.16.
